SoniVie receives IDE approval from FDA for its Pilot study to treat Hypertension with its Renal Artery Denervation TIVUS™ technology
TEL AVIV, Israel, June 20, 2022 /PRNewswire/ -- SoniVie, an Israeli company developing a novel proprietary Therapeutic Intra-Vascular Ultrasound System (TIVUS™) to treat a variety of hypertensive disorders, announced that on May 5th 2022 the U.S. Food and Drug Administration granted IDE approval for its "REDUCED1" Pilot study to treat Resistant Hypertension Patients with Renal Artery Denervation using TIVUS™, its...
2022 Tang Prize in Biopharmaceutical Science Honors Three Scientists for Developing COVID-19 mRNA Vaccines
TAIPEI, Taiwan, June 19, 2022 /PRNewswire/ -- After the 2014 and 2016 winners for the Tang Prize in Biopharmaceutical Sciences were crowned the Nobel Prize in 2018 and 2020 respectively, this category has continued to garner much attention worldwide. After much waiting, names of the latest winners were finally announced at ten (GMT+8) in the morning of June 19....
Memorial MRI & Diagnostic Installs United Imaging’s Pioneering 75 cm, Ultra-Wide-Bore uMR OMEGA™
HOUSTON, June 17, 2022 /PRNewswire/ -- United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment, and Memorial MRI & Diagnostic, a leader in diagnostic and imaging services in Texas, celebrated the installation of new technology for its patients in Katy, TX. According to Todd Greene, COO of Memorial MRI and Diagnostic, the uMR OMEGA...
US FDA AWARDS ORPHAN DRUG DESIGNATION (ODD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER
SYDNEY, June 17, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to Kazia's paxalisib for the treatment of atypical rhabdoid / teratoid tumors (AT/RT), a rare...
HAVAS HEALTH & YOU APPOINTS ELIZABETH EGAN OF HAVAS LYNX TO CEO, HH&Y EUROPE
Appointment Bolsters Capabilities in Fast-Growing European Market Alongside New Havas Lynx Group Leadership NEW YORK, June 17, 2022 /PRNewswire/ -- To support a region that has doubled in size since 2017 and has won over 60% of its pitches in the last year alone, Havas Health & You (HH&Y) today announced that...
Global Cord Blood Corporation Announced Cellenkos Receives FDA Clearance of IND Application for CK0804 as Add on Therapy to Ruxolitinib for the Treatment of Myelofibrosis
HONG KONG, June 17, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, is pleased to announce that Cellenkos, Inc. ("CLNK") recently announced that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug...
Insilico Medicine appoints Dr. Feng Ren as co-CEO
Dr. Feng Ren, Chief Scientific Officer (CSO) and head of global research and development is named co-CEO of Insilico Medicine Highlights: Insilico Medicine is a global, end-to-end, fully-integrated AI-powered biotechnology company with three business models: AI platform, collaboration, and internal pipeline. It utilizes AI and a fully distributed, highly parallel discovery model to rapidly develop its own drugs....
Lunit Files Registration Statement for Initial Public Offering
First Korean healthcare company to obtain "AA-AA" ratings in technology assessment for its FDA-cleared and CE-marked solutions To accelerate listing on the KOSDAQ market within July SEOUL, South Korea, June 16, 2022 /PRNewswire/ -- Lunit, a leading provider of AI solutions for cancer, today announced that it has filed a...
Global Cord Blood Corporation Announces Purported EGM Is Not Validly Convened
HONG KONG, June 16, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO, "GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, noticed that on June 3, 2022 Blue Ocean Structure Investment Company Limited (the "Petitioner") issued a notice which purported to convene an extraordinary general...
Bon Natural Life Limited Introduces New Powder Drink For Anti-H. Pylori and Digestive Health
XI'AN, China, June 16, 2022 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced that it has launched a new cruciferous vegetable based probiotic powder drink that could potentially inhibit the proliferation of Helicobacter pylori and help regulate the...
